IMUNOLOŠKI ODGOVOR NA VAKCINACIJU PROTIV HEPATITISA B KOD VRHUNSKIH SPORTISTA.

IMMUNE RESPONSE TO HEPATITlS B VACCINE IN ELITE ATHLETES.

Introduction Hepatitis B viral infection can create serious health problems, such as acute and chronic hepatitis. cirrhosis of liver and hepatocellular carcinoma. Athletes have bigger risk of hepatitis 8 infection due to frequent injuries with bleeding, their style of living (promiscuity). close contact with teammates, etc. The aim of this study was to investigate the immune response to hepatitis B vaccine among elite athletes, compared to corresponding control group of male subjects from general non-athlete population, and to test out reaction in relation to age. Method There were 21 elite football players and 30 control non-athlete males. After written consent, they all received three doses of hepatitis B vaccine (Euvax B, Sanofi Pasteur) during 6 months. Eight weeks later, their immune response (as anti-HBs antibody titre in serum) was assessed and statistical significance of the findings was tested. The level of immune response was also evaluated in different age clusters within test groups. Results None of the footballers was without response to the vaccine. One of the subjects from the control group did not develop it. The group of athletes was with better mean values of antibody titre (1626621 mIU/ml vs. 1568455 mIU/ml), but without statistical significance (t = 0.375; p > 0.05), and with a greater deal of subjects who developed very good immune response (titre over 2000 mIU/ml). Younger football players had better immune reaction than older (age 18-24, 1795560 mIU/ml, vs. age 25-29 years, 1597470 mIU/ml vs. age 30 and more, 1360904 mIU/ml), but without statistical importance (H = 1593; p > .05). Conclusion Our study has shown that elite athletes respond very well to hepatitis 13 vaccination and have good immune response. Vaccination against hepatitis B of elite athletes is very important, because viral infection can seriously affect their health and stop their careers. [ABSTRACT FROM AUTHOR]

Infekcija hepatitis B virusom može da prouzrokuje značajne zdravstvene probleme, od akutnog i hroničhog hepatitisa, ciroze jetre, do hepatocelularnog karcinoma. Sportisti su pod povećanim rizikom od infekcije virusom hepatitisa B, usled čestog povredivanja sa krvarenjem, bliskih kontakata u kolektivu, promiskuitetnosti i dr. Cilj ove studije je bio da utvrdi kakav imunološki odgovor na vakcinu protiv hepatitisa B razvijaju vrhunski sportisti, uporedeni sa odgovarajućom kontrolnom grupom nesportista. Takode, cilj je bio i da se ispita kakva je reakcija u odnosu na starost ispitanika. Dvadeset jedan vrhunski fudbaler i 30 muškaraca slične starosti primili su tri doze vakcine Euvax B (proizvodač Sanofi Pasteur). Osam nedelja posle završene vakcinacije, merena je imunološka reakcija (kao titar anti-HBs antitela u serumu) u obe grope ispitanika i statistički proveravana značajnost nalaza. Proveravan je i uticaj starosti ispitanika na imunološki odgovor. Svi sportisti su razvili imunološki odgovor na vakcinu, dok jedan ispitanik iz kontrolne grupe nije imao imunološku reakciju. Mladi fudbaleri su razvili bolji imunološki odgovor od starijih kolega. Sportisti su imali prosečno bolji odgovor, sa više ispitanika koji su razvili veoma izražen imunološki odgovor. Naša studija je pokazala da vrhunski sportisti veoma dobro reaguju na vakcinaciju protiv hepatitisa B i razvijaju odličan imunološki odgovor, čak nešto bolji od opšte populacije. Vakcinacija vrhunskih sportista od velikog je značaja, jer infekcija hepatitis B virusom može da dovede do ozbiljnog narušavanja zdravlja i prekida sportske karijere. [ABSTRACT FROM AUTHOR]

Copyright of Medical Review / Medicinski Pregled is the property of National Library of Serbia and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)